Latest Breaking News On - Allosteric modulator - Page 1 : comparemela.com

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Helen rubinsteinHenry gosebruchExchange commissionNeumora therapeutics incTherapeutics reports first quarterProvides businessMajor depressive disorderFourth quarterInitiate phaseDisease agitationSecond quarterAllosteric modulatorAdvancing preclinical work acrossUnited kingdomNeumora therapeuticsPrivate securities litigation reform act

STALICLA: Stalicla Secures $17 4 Million in Series B Financing to Propel Precision Neuro Advancements

STALICLA: Stalicla Secures $17 4 Million in Series B Financing to Propel Precision Neuro Advancements
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesLynn durhamNational institute on drug abuseManagement teamGlobal investments pte ltdInvestments pteAutism spectrum disorderAllosteric modulatorSubstance use disordersNational instituteDrug abuse

Stalicla Secures $17 4 Million in Series B Financing to Propel Precision Neuro Advancements

Stalicla Secures $17 4 Million in Series B Financing to Propel Precision Neuro Advancements
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesLynn durhamManagement teamGlobal investments pte ltdNational institute on drug abuseSeriesb financingPropel precision neuroInvestments pteAutism spectrum disorderAllosteric modulatorSubstance use disordersNational instituteDrug abuse

Stalicla Raises $17 4M in Series B Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

United statesLynn durhamGlobal investments pte ltdNational institute on drug abuseInvestments pteAutism spectrum disorderAllosteric modulatorSubstance use disordersNational instituteDrug abuse

Addex Regains Nasdaq Listing Compliance

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 8, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced it had received written notification from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the minimum bid price requirement of $1.00 per ADS under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable cr

United statesMike sinclairTim dyerSwiss exchangeNasdaq stock marketNasdaq listing ruleAddex therapeuticsAmerican depositary sharesAllosteric modulatorDrug discovery and developmentDrug discovery